SCHEMBL2932639

SCHEMBL2932639

CN1CCN(C(=O)c2ccc(Nc3cncc(Cl)n3)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
GRM5 P41594 7/20 0.51
SRC P12931 5/20 0.50
KMT2A Q03164 1/20 0.49
CCNT1 O60563 1/20 0.48
CDK4 P11802 1/20 0.48
CCND1 P24385 1/20 0.48
CDK9 P50750 1/20 0.48
CDK6 Q00534 1/20 0.48
CDK11A Q9UQ88 1/20 0.48
EPHX2 P34913 1/20 0.48
CDK2 P24941 2/20 0.48
PDGFRB P09619 3/20 0.48
ABL1 P00519 1/20 0.47
KIT P10721 1/20 0.47
PDGFRA P16234 1/20 0.47
MAPK14 Q16539 1/20 0.47
WEE1 P30291 1/20 0.47
MAPKAPK2 P49137 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2933155 0.83 GRM5 (0.58) POLBGRM5KMT2ACCNT1CDK9
SCHEMBL2932963 0.80 CHEK1 (0.58) POLBSRCCCNT1CDK4CCND1
SCHEMBL2928621 0.77 ATR (0.52) SRCKMT2AEPHX2CDK2ABL1
SCHEMBL2932811 0.76 CDK2 (0.66) POLBKMT2ACDK4CCND1CDK2
Trifluoroacetic Acid SCHEMBL2928619 0.75 CHEK1 (0.52) POLBSRCEPHX2CDK2ABL1
SCHEMBL2931520 0.75 HRH4 (0.55) SRCCCNT1CDK4CCND1CDK9
SCHEMBL28153695 0.75 LRRK2 (0.54) POLBSRCKMT2AEPHX2CDK2
SCHEMBL12814065 0.74 HRH4 (0.50) POLBKMT2A
SCHEMBL712714 0.74 RAB9A (0.68) POLBGRM5KMT2A
SCHEMBL14409686 0.74 ALDH1A1 (0.60) POLBGRM5KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
CN-101472912-A Pyridine and pyrazine derivatives as MNK kinase inhibitors BIOVITRUM AB PUBL (SE) 2009-07-01 CN disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 POLB 1721/4885GRM5 1026/4885SRC 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.